Bionor Immuno AS Company Profile

02:48 EST 20th November 2017 | BioPortfolio

Bionor Immuno is a multidisciplinary drug discovery company located in Skien, Norway. The major focus of the company is to develop effective peptide based immunotherapies, against infectious diseases for which there is currently no effective vaccine or where existing treatments are poorly effective. Bionor Immuno AS aims to develop its therapeutic products through phase II clinical trials. Phase III clinical trials, manufacturing and marketing of finished products will be done in co-operation with a licensing partner


P.O. Box 1823


Phone: 47 35 50 57 50
Fax: 47 35 50 57 01

News Articles [273 Associated News Articles listed on BioPortfolio]

Is immuno-oncology shaping the oncology product development landscape?

Steven Powell, chief executive of UK-based immuno-oncology (I-O) company Macrophage Pharma, gives an…

Cancer Research UK Teams Up with London Startup in Immuno-oncology

Biotecnol, based in London, has found a partner in CRUK to bring its immune-stimulating antibody into the clinic to tackle solid tumors. There will (probably) be a new immuno-oncology drug on the bloc...

Tesaro partners with Evotec on immuno-oncology study

Tesaro signed a three-year deal with Evotec that aims to develop small-molecule inhibitors against an undisclosed immuno-onco -More- 

Belgian Biotech Grows its Pipeline of Immuno-Oncology Therapies

Oncurious has licensed five immuno-oncology candidates developed at VIB to expand its pipeline of cancer therapies. The young Belgian biotech Oncurious has decided to step up its game through an agree...

PeptiDream collaborates with Kleo for immuno-oncology drug research

Tokyo-based PeptiDream agreed to work with Kleo Pharmaceuticals on the development of immuno-oncology drugs for multiple indi -More- 

End-to-end drug & diagnostic development support for a new immuno-oncology agent: A case study

Immuno-oncology drug development is inherently complex and requires special considerations across the entire spectrum.

BMS to use Halozyme’s Enhanze technology to develop immuno-oncology medicines

Bristol-Myers Squibb (BMS) has partnered with Halozyme Therapeutics for the development of immuno-oncology medicines.

Belgian Biotech Grows its Immuno-Oncology Pipeline for Childhood Cancer

Oncurious has licensed five immuno-oncology candidates developed at VIB to expand its pipeline of cancer therapies for children. The young Belgian biotech Oncurious has decided to step up its game thr...

Drugs and Medications [0 Results]


PubMed Articles [80 Associated PubMed Articles listed on BioPortfolio]

Disseminated histoplasmosis in an immuno-competent young male: Role of bone marrow examination in rapid diagnosis.

Fungal infections are usually seen in elderly or immuno-compromised individuals particularly with human immunodeficiency virus infection. In immuno-competent individuals, they seldom present with over...

A Case for a Human Immuno-Peptidome Project Consortium.

A multidisciplinary group of researchers gathered at the Hönggerberg Campus at ETH Zurich, Switzerland, for the first meeting on the Human Immuno-Peptidome Project (

Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation.

New immuno-oncology (I-O) therapies that harness the immune system to fight cancer call for a re-examination of the traditional parametric techniques used to model survival from clinical trial data. M...

Checkpoint inhibitors: a cutting edge in oncology.

The checkpoint inhibitor field, and indeed the whole of immuno-oncology, is fast-paced and fascinating, with huge clinical and commercial potential. The challenge in the coming years will be to define...

The Challenge for Development of Valuable Immuno-oncology Biomarkers.

The development of immunotherapy is an important breakthrough for the treatment of cancer, with antitumor efficacy observed in a wide variety of tumors. To optimize immunotherapy use, approaches must ...

Clinical Trials [755 Associated Clinical Trials listed on BioPortfolio]

Exposure Chamber Trial With Cat Immunotherapy

The main purpose of this trial is to investigate if any of three different doses of cat hair immunotherapy is safe for treatment of cat allergic patients.

Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy

We wanted to examine the immunogenicity and safety of a shortened specific immunotherapy in contrast to the standard specific immunotherapy. Therefore, we challenged 12 patients for 14 we...

Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy

The study evaluates the safety and effect of intralymphatic allergen specific immunotherapy in increasing doses. Patients that have already undergone subcutaneous immunotherapy will be tre...

Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma

The purpose of this study is to determine the safety of making and giving Epstein-Barr virus (EBV) immunotherapy products to subjects with nasopharyngeal carcinoma (NPC) associated with EB...

The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy

The purpose of this study is to determine if small oral and sublingual doses of milk protein are safe and effective in decreasing sensitivity to cow's milk in allergic children.

Companies [74 Associated Companies listed on BioPortfolio]

Bionor Immuno AS

Bionor Immuno is a multidisciplinary drug discovery company located in Skien, Norway. The major focus of the company is to develop effective peptide based immunotherapies, against infectious diseases ...

Bionor AS

Bionor is a biotechnology company founded in 1985 developing products for human and veterinarian medicine including aqua culture. For the last 10 years Bionor has increased its HIV related activities ...

Immuno Laboratories

Headquartered in Fort Lauderdale, Florida, Immuno Laboratories is widely recognized as one of the leading food and environmental allergy testing facilities in the world. Since 197...

Immunotech Laboratories, Inc.

Headquartered in Monrovia, CA, Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitati...


SDI is a leading healthcare market insight and analytics firm. It provides the industry’s most comprehensive de-identified patient-level data to pharmaceutical, biotech, reta...

More Information about "Bionor Immuno AS" on BioPortfolio

We have published hundreds of Bionor Immuno AS news stories on BioPortfolio along with dozens of Bionor Immuno AS Clinical Trials and PubMed Articles about Bionor Immuno AS for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Bionor Immuno AS Companies in our database. You can also find out about relevant Bionor Immuno AS Drugs and Medications on this site too.

Quick Search

Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Corporate Database Quicklinks

Searches Linking to this Company Record